Volpara Health Technologies Limited (VPAHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Volpara Health Technologies Limited (VPAHF) with AI Score 60/100 (Hold). Volpara Health Technologies Limited provides breast imaging analytics software, aiming to improve early breast cancer detection and screening efficiency. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Volpara Health Technologies Limited (VPAHF) Healthcare & Pipeline Overview
Volpara Health Technologies Limited offers breast imaging analytics software, utilizing AI-driven solutions to optimize breast cancer screening operations and improve clinical decision-making. Their focus on early detection and personalized risk assessment positions them within the growing healthcare information services sector, serving North America, APAC, EMEA.
Investment Thesis
Volpara Health Technologies Limited presents an investment opportunity within the growing healthcare information services sector, specifically in breast cancer screening and early detection. The company's AI-driven software solutions, such as Volpara Analytics and Volpara Risk, address the increasing demand for personalized and efficient screening processes. While the company currently operates with a negative profit margin of -28.0%, its high gross margin of 76.8% indicates strong potential for profitability as it achieves greater scale. Key catalysts include expanding market penetration in North America and Europe, and further development of its AI-powered technologies. Investors should monitor the company's ability to achieve profitability and manage its cash burn rate. The company's beta of 1.67 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.19 billion, reflecting its position as a smaller player in the healthcare IT market.
- Negative P/E ratio of -32.34, indicating current lack of profitability but potential for future earnings growth.
- Gross margin of 76.8%, showcasing the high value and pricing power of its software solutions.
- Operating in North America, APAC, and EMEA, demonstrating a global presence and market reach.
- Strategic relationship with RevealDx, potentially enhancing its product offerings and market access.
Competitors & Peers
Strengths
- Proprietary AI-powered software solutions
- High gross margin
- Established customer base
- Global presence
Weaknesses
- Negative profit margin
- Reliance on subscription revenue
- Limited brand recognition compared to larger competitors
- OTC listing may limit investor access
Catalysts
- Upcoming: Expansion of Volpara's AI-powered solutions into new markets and applications.
- Ongoing: Increasing adoption of breast cancer screening programs globally.
- Ongoing: Strategic partnerships with healthcare providers and technology companies.
- Upcoming: Development of new features and functionalities for Volpara's software solutions.
Risks
- Potential: Competition from larger healthcare IT companies with greater resources.
- Potential: Regulatory changes in healthcare impacting reimbursement rates or screening guidelines.
- Potential: Economic downturn leading to reduced healthcare spending.
- Potential: Data security and privacy breaches compromising patient information.
- Ongoing: The company's current lack of profitability and reliance on external funding.
Growth Opportunities
- Expansion in North America: Volpara has the opportunity to further penetrate the North American market, which represents a significant portion of the global breast cancer screening market. By expanding its sales and marketing efforts and establishing partnerships with leading healthcare providers, Volpara can increase its market share and drive revenue growth. The North American breast cancer screening market is projected to reach billions of dollars in the coming years, offering a substantial growth opportunity for Volpara.
- Product Innovation and AI Development: Continued investment in research and development to enhance its AI-powered software solutions is crucial for Volpara's long-term growth. By developing new features and functionalities, such as improved risk assessment models and personalized screening recommendations, Volpara can strengthen its competitive advantage and attract new customers. The company's Volpara Science division plays a key role in driving product innovation and AI development.
- Strategic Partnerships and Acquisitions: Volpara can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. By collaborating with complementary technology providers or acquiring companies with innovative solutions in adjacent areas, Volpara can enhance its value proposition and accelerate its growth. The company's existing strategic relationship with RevealDx demonstrates its commitment to partnerships.
- Expansion into Lung Cancer Screening: Leveraging its expertise in medical imaging analytics, Volpara can expand its offerings into lung cancer screening. With the increasing adoption of lung cancer screening programs, there is a growing demand for software solutions that streamline workflows and improve detection rates. Volpara Lung is a step in this direction, and further development in this area could unlock a new growth avenue.
- Data Analytics and Personalized Medicine: Volpara can leverage its vast database of breast imaging data to develop personalized medicine solutions. By analyzing patient data and identifying individual risk factors, Volpara can provide tailored screening recommendations and improve patient outcomes. The growing trend towards personalized medicine presents a significant opportunity for Volpara to differentiate itself and create new revenue streams.
Opportunities
- Expansion in North America and Europe
- Product innovation and AI development
- Strategic partnerships and acquisitions
- Expansion into lung cancer screening
Threats
- Competition from larger healthcare IT companies
- Regulatory changes in healthcare
- Economic downturn impacting healthcare spending
- Data security and privacy concerns
Competitive Advantages
- Proprietary AI Algorithms: Volpara's AI-powered software solutions provide a competitive advantage in terms of accuracy and efficiency.
- Data Network Effects: The company's vast database of breast imaging data creates a network effect, making its solutions more valuable as more data is collected.
- Established Customer Base: Volpara has an established customer base of hospitals, imaging centers, and healthcare providers.
About VPAHF
Volpara Health Technologies Limited, founded in 2009 and headquartered in Wellington, New Zealand, is a healthcare technology company focused on developing and providing breast imaging analytics software. The company's mission is to improve early breast cancer detection and screening efficiency through innovative technology solutions. Volpara's core offerings include Volpara Analytics, a software platform designed to optimize breast cancer screening operations by providing data-driven insights into image quality and workflow efficiency. Volpara Live offers real-time image quality feedback during mammography exams. Volpara Lung streamlines lung screening workflows, while Volpara Patient Hub provides customizable mammography reporting and patient communication tools. The company also offers Volpara Risk, which integrates with Patient Hub to calculate a patient's risk of developing breast cancer using the TC8 model. Volpara Risk Pathways is a program designed for identifying and managing high-risk breast cancer screening patients. Volpara Scorecard displays patient breast density and risk insights. Volpara Science powers the company's software products with AI. Additional clinical functions include TruDensity, TruPGMI, TruPressure, and TruRadDose. Volpara operates in North America, the Asia Pacific, Europe, the Middle East, and Africa, serving a global network of healthcare providers and imaging centers. The company has a strategic relationship with RevealDx.
What They Do
- Provides software to optimize breast cancer screening operations.
- Offers real-time image quality feedback during mammography exams.
- Streamlines lung screening workflows.
- Provides customizable mammography reporting and patient communication tools.
- Calculates a patient's risk of developing breast cancer.
- Displays patient breast density and risk insights.
- Powers its software products with AI.
Business Model
- Software as a Service (SaaS): Volpara generates revenue through subscription fees for its software solutions.
- Data Analytics: The company leverages its database of breast imaging data to provide analytics and insights to healthcare providers.
- Partnerships: Volpara collaborates with other technology providers to expand its product portfolio and market reach.
Industry Context
Volpara Health Technologies Limited operates within the healthcare information services industry, a sector experiencing growth driven by the increasing adoption of digital health solutions, the rising prevalence of chronic diseases like breast cancer, and the growing emphasis on preventive care. The market is competitive, with established players like ADOCY (Accenture), AMGXF (Allscripts Healthcare Solutions), BRNHF (athenahealth), DLHTF (Cerner Corporation), and EKDHF (Elevance Health) offering a range of healthcare IT solutions. Volpara differentiates itself through its focus on breast imaging analytics and AI-powered risk assessment, catering to the specific needs of breast cancer screening programs.
Key Customers
- Hospitals and imaging centers
- Breast cancer screening programs
- Healthcare providers
Financials
Chart & Info
Volpara Health Technologies Limited (VPAHF) stock price: Price data unavailable
Latest News
No recent news available for VPAHF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VPAHF.
Price Targets
Wall Street price target analysis for VPAHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates VPAHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Teri Jo Thomas
CEO
Teri Jo Thomas serves as the CEO of Volpara Health Technologies Limited, leading a team of 156 employees. Information regarding Teri Jo Thomas's detailed career history, education, and previous roles is not available in the provided data. However, as CEO, she is responsible for the overall strategic direction and operational performance of the company.
Track Record: Information regarding Teri Jo Thomas's specific achievements, strategic decisions, and company milestones under her leadership is not available in the provided data. Her role involves overseeing the development and commercialization of Volpara's breast imaging analytics software and expanding the company's market presence.
VPAHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Volpara Health Technologies Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and trading volume
- Less stringent regulatory oversight
- Potential for price volatility
- Information asymmetry due to limited financial disclosure
- Higher risk of fraud or manipulation
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and market opportunities.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established business operations since 2009
- Presence in North America, APAC, and EMEA
- Strategic relationship with RevealDx
- Focus on a specific niche market (breast imaging analytics)
Volpara Health Technologies Limited Stock: Key Questions Answered
What does Volpara Health Technologies Limited do?
Volpara Health Technologies Limited specializes in developing and providing AI-powered breast imaging analytics software. Their solutions are designed to optimize breast cancer screening operations, improve image quality, assess patient risk, and streamline clinical workflows. The company's products, such as Volpara Analytics and Volpara Risk, are used by hospitals, imaging centers, and healthcare providers to enhance early breast cancer detection and personalized screening programs. Volpara operates globally, serving customers in North America, the Asia Pacific, Europe, the Middle East, and Africa.
What do analysts say about VPAHF stock?
As of 2026-03-16, a comprehensive analyst consensus on VPAHF stock is not available within the provided data. Investors should conduct their own due diligence and consult with financial professionals to assess the company's valuation, growth prospects, and risk factors. Key metrics to consider include the company's market capitalization, revenue growth, gross margin, and profitability. The company's position in the healthcare information services industry and its competitive landscape should also be taken into account.
What are the main risks for VPAHF?
Volpara Health Technologies Limited faces several risks, including competition from larger healthcare IT companies, regulatory changes in healthcare, economic downturns impacting healthcare spending, and data security and privacy breaches. The company's current lack of profitability and reliance on external funding also pose risks to its financial stability. Additionally, as an OTC-listed stock, VPAHF is subject to greater liquidity risk and price volatility compared to stocks listed on major exchanges. Investors should carefully consider these risks before investing in VPAHF.
What are the key factors to evaluate for VPAHF?
Volpara Health Technologies Limited (VPAHF) currently holds an AI score of 60/100, indicating moderate score. Key strength: Proprietary AI-powered software solutions. Primary risk to monitor: Potential: Competition from larger healthcare IT companies with greater resources.. This is not financial advice.
How frequently does VPAHF data refresh on this page?
VPAHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VPAHF's recent stock price performance?
Recent price movement in Volpara Health Technologies Limited (VPAHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary AI-powered software solutions. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VPAHF overvalued or undervalued right now?
Determining whether Volpara Health Technologies Limited (VPAHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VPAHF?
Before investing in Volpara Health Technologies Limited (VPAHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited or delayed.
- AI analysis is pending and may provide further insights.